4.5 Article

Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events

Journal

EPILEPSIA
Volume 62, Issue 7, Pages 1604-1616

Publisher

WILEY
DOI: 10.1111/epi.16930

Keywords

cardiovascular risk; enzyme-inducing antiepileptic drugs

Funding

  1. Health Data Research UK from HDR UK - UK Medical Research Council [HDR-9006]
  2. Engineering and Physical Sciences Research Council
  3. Economic and Social Research Council
  4. Department of Health and Social Care (England)
  5. Chief Scientist Office of the Scottish Government Health and Social Care Directorates
  6. Health and Social Care Research and Development Division (Welsh Government)
  7. Public Health Agency (Northern Ireland)
  8. British Heart Foundation
  9. Wellcome Trust
  10. Brain Repair and Intracranial Neurotherapeutics (BRAIN) Unit Infrastructure Award [UA05]
  11. Welsh Government through Health and Care Research Wales

Ask authors/readers for more resources

This study investigated the association between epilepsy, antiepileptic drugs, and major cardiovascular events using population-level data. The results indicated that individuals with epilepsy prescribed antiepileptic drugs are at an increased risk of experiencing major cardiovascular events, highlighting the importance of cardiovascular risk management in epilepsy care.
Objective This study was undertaken to determine whether epilepsy and antiepileptic drugs (including enzyme-inducing and non-enzyme-inducing drugs) are associated with major cardiovascular events using population-level, routinely collected data. Methods Using anonymized, routinely collected, health care data in Wales, UK, we performed a retrospective matched cohort study (2003-2017) of adults with epilepsy prescribed an antiepileptic drug. Controls were matched with replacement on age, gender, deprivation quintile, and year of entry into the study. Participants were followed to the end of the study for the occurrence of a major cardiovascular event, and survival models were constructed to compare the time to a major cardiovascular event (cardiac arrest, myocardial infarction, stroke, ischemic heart disease, clinically significant arrhythmia, thromboembolism, onset of heart failure, or a cardiovascular death) for individuals in the case group versus the control group. Results There were 10 241 cases (mean age = 49.6 years, 52.2% male, mean follow-up = 6.1 years) matched to 35 145 controls. A total of 3180 (31.1%) cases received enzyme-inducing antiepileptic drugs, and 7061 (68.9%) received non-enzyme-inducing antiepileptic drugs. Cases had an increased risk of experiencing a major cardiovascular event compared to controls (adjusted hazard ratio = 1.58, 95% confidence interval [CI] = 1.51-1.63, p < .001). There was no notable difference in major cardiovascular events between those treated with enzyme-inducing antiepileptic drugs and those treated with non-enzyme-inducing antiepileptic drugs (adjusted hazard ratio = .95, 95% CI = .86-1.05, p = .300). Significance Individuals with epilepsy prescribed antiepileptic drugs are at an increased risk of major cardiovascular events compared with population controls. Being prescribed an enzyme-inducing antiepileptic drug is not associated with a greater risk of a major cardiovascular event compared to treatment with other antiepileptic drugs. Our data emphasize the importance of cardiovascular risk management in the clinical care of people with epilepsy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available